Phaseline

Companies › SciTech Development

SciTech Development: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ST-001 nanoFenretinide (Fenretinide)
Retinoid X receptor (RXR) agonist; pro-apoptotic retinoid with activity in lymphomas
RXRA, RXRB, RXRGPhase 1Small Cell Lung Cancer; T-cell LymphomaMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06922539ST-001 nanoFenretinide (Fenretinide)Phase 1Small Cell Lung CancerOncologyMay 2027
NCT04234048ST-001 nanoFenretinide (Fenretinide)Phase 1T-cell LymphomaOncologyJun 2028

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

RXRA (1) RXRB (1) RXRG (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.